Literature DB >> 14638341

Chronic acid-related disorders are common and underinvestigated.

Sumit R Majumdar1, Stephen B Soumerai, Francis A Farraye, Marianne Lee, James A Kemp, James M Henning, Peggy Schrammel, Robert F LeCates, Dennis Ross-Degnan.   

Abstract

OBJECTIVES: The aims of this study were as follows: to establish the prevalence of chronic acid-related disorders in a managed care population; to describe these patients; and to examine rates of adherence to current guidelines for investigation of dyspepsia and peptic ulcer disease.
METHODS: The design was a population-based cohort study. The sample was drawn from 216,720 adult (aged >18 yr) members of a managed care organization that had an electronic medical record linked to administrative and pharmacy databases. We included adults with continuous enrollment from July, 1998, to January, 2000, who were dispensed histamine-2 blockers or proton-pump inhibitors, or both, for > or =1 yr. Dispensing data, sociodemographic and clinical information, comorbidities, and investigations were collected and analyzed.
RESULTS: The final cohort consisted of 5064 patients; 64% were aged > or =50 yr, 47% were male, and 11% were African American. The prevalence of chronic acid-related disorders was 2.3%. Gastroesophageal reflux disease (59%) was the most common condition, followed by dyspepsia (35% of cohort; 18% investigated by endoscopy). There were 917 dyspepsia patients > or =50 yr who had not been investigated by endoscopy (81% of dyspepsia patients in this age group). There were 97 patients with peptic ulcer disease who did not have a documented test for Helicobacter pylori (34% of patients with peptic ulcer disease).
CONCLUSIONS: Chronic acid-related disorders are common in primary care, and many patients use acid suppressing medications on a long-term basis. Nevertheless, according to current practice guidelines, our patients were underinvestigated. Future guidelines should specifically address the management of patients who use acid suppressing medications on a chronic basis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638341     DOI: 10.1111/j.1572-0241.2003.07706.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 2.  Dyspepsia and its overlap with irritable bowel syndrome.

Authors:  William M Outlaw; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2006-08

3.  Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers.

Authors:  B M R Spiegel; M Farid; M G H van Oijen; L Laine; C W Howden; E Esrailian
Journal:  Aliment Pharmacol Ther       Date:  2009-01-15       Impact factor: 8.171

4.  Gastroesophageal reflux disease symptoms are more common in general practice in Japan.

Authors:  Toshiyasu Watanabe; Yoshihisa Urita; Motonobu Sugimoto; Kazumasa Miki
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

5.  A new method for determining gastric acid output using a wireless pH-sensing capsule.

Authors:  D H Weinstein; S deRijke; C C Chow; L Foruraghi; X Zhao; E C Wright; M Whatley; R Maass-Moreno; C C Chen; S A Wank
Journal:  Aliment Pharmacol Ther       Date:  2013-05-03       Impact factor: 8.171

Review 6.  Overtesting and undertesting in primary care: a systematic review and meta-analysis.

Authors:  Jack W O'Sullivan; Ali Albasri; Brian D Nicholson; Rafael Perera; Jeffrey K Aronson; Nia Roberts; Carl Heneghan
Journal:  BMJ Open       Date:  2018-02-11       Impact factor: 2.692

7.  Guideline Adherence in Dyspepsia Investigation and Treatment.

Authors:  Katelyn Dugan; Elizabeth Ablah; Hayrettin Okut; Sachin Srinivasan; William Salyers
Journal:  Kans J Med       Date:  2020-12-11

8.  Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Authors:  Vijay V Upreti; Yan Song; Jessie Wang; Wonkyung Byon; Rebecca A Boyd; Janice M Pursley; Frank Lacreta; Charles E Frost
Journal:  Clin Pharmacol       Date:  2013-04-16

Review 9.  Long-term management of GERD in the elderly with pantoprazole.

Authors:  Carlo Calabrese; Anna Fabbri; Giulio Di Febo
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Dyspepsia management in a resource poor setting.

Authors:  A C Jemilohun; J O Fadare
Journal:  Ann Ib Postgrad Med       Date:  2013-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.